AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Corcept Therapeutics Incorporated
Video analysis: CORT
All videosNo video analysis for this stock yet. Request one from our team.
News: CORT
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
Corcept: Not Cheap, But Backed By Real Structural Growth
Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.
Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT
Bank of America Corp DE raised its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 33.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 111,736 shares of the biotechnology company's stock after acquiring an additional 28,078 shares during the period. Bank
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT
Bank of New York Mellon Corp acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 565,666 shares of the biotechnology company's stock, valued at approximately $49,185,000. Bank of New York Mellon Corp owned approximately
BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT
BlackRock Inc. bought a new stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,432,023 shares of the biotechnology company's stock, valued at approximately $1,080,964,000. BlackRock Inc. owned about 11.50% of
Like The Knick's, Corcept Rebounded And Is Crushing It
Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.
Mega Cap Growth vs Small Cap Growth: Which ETF Wins?
MGK offers lower costs and mega-cap stability; SLYG delivered 27.4% returns over one year with broader diversification across industrials and healthcare.
